Itshak Golan has completed his PhD in Cell Research and Immunology, Tel-Aviv University and Postdoctoral studies in Hebrew University Medical School of Jerusalem and B.T.G. Israel Ltd. He was the Lecturer in Hebrew University Medical School, Honorary Principal Research Fellow in Imperial College, Honorary Senior Lecturer in College of Medicine, Swansea University, R&D/Innovation Manager in Swansea University and Senior Program Manager in NIHR. He is a Founder and Director of two British Biotechnology Companies developing new biological drugs for autoimmune inflammatory diseases and cancer and serving as an Expert/Projects Evaluator in EU Commission in Brussels. He was awarded for his professional success by Hebrew University and EU Commission. He has published 15 papers in scientific journals, has 36 patents in the field of rheumatoid arthritis and cancer and has been serving as an Editorial Board Member of MOJ Immunology Itshak Golan has completed his PhD in Cell Research and Immunology, Tel-Aviv University and Postdoctoral studies in Hebrew University Medical School of Jerusalem and B.T.G. Israel Ltd. He was the Lecturer in Hebrew University Medical School, Honorary Principal Research Fellow in Imperial College, Honorary Senior Lecturer in College of Medicine, Swansea University, R&D/Innovation Manager in Swansea University and Senior Program Manager in NIHR. He is a Founder and Director of two British Biotechnology Companies developing new biological drugs for autoimmune inflammatory diseases and cancer and serving as an Expert/Projects Evaluator in EU Commission in Brussels. He was awarded for his professional success by Hebrew University and EU Commission. He has published 15 papers in scientific journals, has 36 patents in the field of rheumatoid arthritis and cancer and has been serving as an Editorial Board Member of MOJ Immunology

Reproductive Medicine